#1•05 באוג׳ 2026, 14:38•Jerusalem Post•news_site
SIL204 treatment may help immune system attack KRAS-driven tumors, research finds - exclusive
This comes just after SIL204 advanced into Phase 2/3 clinical evaluation at the end of July, beginning its first clinical trial at Tel Aviv Sourasky Medical Center.
דחיפות 2/5major_media
פתח מקור מקורי ↗